
Jared Barsky
Examiner (ID: 7259, Phone: (571)272-2795 , Office: P/1628 )
| Most Active Art Unit | 1628 |
| Art Unit(s) | 1628 |
| Total Applications | 1117 |
| Issued Applications | 492 |
| Pending Applications | 146 |
| Abandoned Applications | 503 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 14621631
[patent_doc_number] => 20190224183
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-25
[patent_title] => Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists
[patent_app_type] => utility
[patent_app_number] => 16/369594
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7547
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16369594
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/369594 | Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists | Mar 28, 2019 | Abandoned |
Array
(
[id] => 14578385
[patent_doc_number] => 20190216801
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
[patent_app_type] => utility
[patent_app_number] => 16/364463
[patent_app_country] => US
[patent_app_date] => 2019-03-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31669
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364463
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/364463 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Mar 25, 2019 | Abandoned |
Array
(
[id] => 14578383
[patent_doc_number] => 20190216800
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-07-18
[patent_title] => DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
[patent_app_type] => utility
[patent_app_number] => 16/364005
[patent_app_country] => US
[patent_app_date] => 2019-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -24
[patent_words_short_claim] => 78
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16364005
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/364005 | DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION | Mar 24, 2019 | Abandoned |
Array
(
[id] => 14681947
[patent_doc_number] => 20190240088
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-08
[patent_title] => METHODS AND COMPOSITIONS FOR TREATMENT OF SKIN CONDITIONS
[patent_app_type] => utility
[patent_app_number] => 16/362600
[patent_app_country] => US
[patent_app_date] => 2019-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4383
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 58
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16362600
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/362600 | Methods and compositions for treatment of skin conditions | Mar 21, 2019 | Issued |
Array
(
[id] => 14991105
[patent_doc_number] => 20190314510
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-10-17
[patent_title] => METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM
[patent_app_type] => utility
[patent_app_number] => 16/359878
[patent_app_country] => US
[patent_app_date] => 2019-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 22106
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16359878
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/359878 | METHODS AND COMPOSITIONS FOR THE SUSTAINED RELEASE OF CHROMIUM | Mar 19, 2019 | Abandoned |
Array
(
[id] => 18700011
[patent_doc_number] => 11786497
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-17
[patent_title] => High penetration prodrug compositions of retinoids and retinoids-related compounds
[patent_app_type] => utility
[patent_app_number] => 16/299560
[patent_app_country] => US
[patent_app_date] => 2019-03-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 15416
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 409
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16299560
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/299560 | High penetration prodrug compositions of retinoids and retinoids-related compounds | Mar 11, 2019 | Issued |
Array
(
[id] => 16296153
[patent_doc_number] => 20200281876
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-10
[patent_title] => Topical Preparation for the Treatment of Arthritis and Skin Conditions
[patent_app_type] => utility
[patent_app_number] => 16/296029
[patent_app_country] => US
[patent_app_date] => 2019-03-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4275
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16296029
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/296029 | Topical Preparation for the Treatment of Arthritis and Skin Conditions | Mar 6, 2019 | Abandoned |
Array
(
[id] => 14743933
[patent_doc_number] => 20190255140
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-22
[patent_title] => USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
[patent_app_type] => utility
[patent_app_number] => 16/294615
[patent_app_country] => US
[patent_app_date] => 2019-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13099
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16294615
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/294615 | USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS | Mar 5, 2019 | Abandoned |
Array
(
[id] => 15381761
[patent_doc_number] => 10532037
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-01-14
[patent_title] => Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss
[patent_app_type] => utility
[patent_app_number] => 16/292473
[patent_app_country] => US
[patent_app_date] => 2019-03-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5966
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16292473
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/292473 | Oral combination drug formulation comprising a non-steroidal anti-inflammatory drug and a complementary low dose of tranexamic acid for the treatment of menstrual pain accompanied with excessive menstrual blood loss | Mar 4, 2019 | Issued |
Array
(
[id] => 14497705
[patent_doc_number] => 20190192507
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-06-27
[patent_title] => BUPROPION AS A MODULATOR OF DRUG ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 16/290653
[patent_app_country] => US
[patent_app_date] => 2019-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 46261
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 47
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16290653
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/290653 | BUPROPION AS A MODULATOR OF DRUG ACTIVITY | Feb 28, 2019 | Abandoned |
Array
(
[id] => 19075291
[patent_doc_number] => 11944634
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-04-02
[patent_title] => Tetracycline compositions
[patent_app_type] => utility
[patent_app_number] => 16/287639
[patent_app_country] => US
[patent_app_date] => 2019-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 17873
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16287639
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/287639 | Tetracycline compositions | Feb 26, 2019 | Issued |
Array
(
[id] => 18792628
[patent_doc_number] => 11826361
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-11-28
[patent_title] => Use of pridopidine for treating dystonias
[patent_app_type] => utility
[patent_app_number] => 16/283784
[patent_app_country] => US
[patent_app_date] => 2019-02-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 64
[patent_no_of_words] => 18930
[patent_no_of_claims] => 14
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16283784
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/283784 | Use of pridopidine for treating dystonias | Feb 23, 2019 | Issued |
Array
(
[id] => 16946630
[patent_doc_number] => 20210205321
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => AGONISTS OF STIMULATOR OF INTERFERON GENES STING
[patent_app_type] => utility
[patent_app_number] => 15/733535
[patent_app_country] => US
[patent_app_date] => 2019-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9554
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15733535
[rel_patent_id] =>[rel_patent_doc_number] =>) 15/733535 | Agonists of stimulator of interferon genes sting | Feb 20, 2019 | Issued |
Array
(
[id] => 16569024
[patent_doc_number] => 20210008030
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-14
[patent_title] => METHODS OF TREATING SOCIAL FUNCTION DISORDERS
[patent_app_type] => utility
[patent_app_number] => 16/970089
[patent_app_country] => US
[patent_app_date] => 2019-02-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21857
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16970089
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/970089 | METHODS OF TREATING SOCIAL FUNCTION DISORDERS | Feb 14, 2019 | Abandoned |
Array
(
[id] => 17405454
[patent_doc_number] => 11246310
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-02-15
[patent_title] => Insect repelling composition
[patent_app_type] => utility
[patent_app_number] => 16/270857
[patent_app_country] => US
[patent_app_date] => 2019-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4762
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270857
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/270857 | Insect repelling composition | Feb 7, 2019 | Issued |
Array
(
[id] => 14682119
[patent_doc_number] => 20190240174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-08
[patent_title] => USE OF (1S,3S)-3-AMINO-4-(DIFLUOROMETHYLIDENE) CYCLOPENTANE-1-CARBOXYLIC ACID AND (S)-3-AMINO-4-(DIFLUOROMETHYLENYL)CYCLOPENT-1-ENE-1-CARBOXYLIC ACID IN THE TREATMENT OF TINNITUS, ACUTE SENSORINEURAL HEARING LOSS, MENIERE'S DISEASE, TOURETTE'S SYNDROME, ATTENTION DEFICIT HYPERACTIVITY DISORDER AND ADDICTION
[patent_app_type] => utility
[patent_app_number] => 16/270856
[patent_app_country] => US
[patent_app_date] => 2019-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26435
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16270856
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/270856 | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, meniere'S disease, tourette'S syndrome, attention deficit hyperactivity disorder and addiction | Feb 7, 2019 | Issued |
Array
(
[id] => 15306349
[patent_doc_number] => 10517855
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2019-12-31
[patent_title] => Interleukins activity inhibiting composition
[patent_app_type] => utility
[patent_app_number] => 16/271644
[patent_app_country] => US
[patent_app_date] => 2019-02-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4526
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16271644
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/271644 | Interleukins activity inhibiting composition | Feb 7, 2019 | Issued |
Array
(
[id] => 15163211
[patent_doc_number] => 10487085
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2019-11-26
[patent_title] => Purinone derivative
[patent_app_type] => utility
[patent_app_number] => 16/269744
[patent_app_country] => US
[patent_app_date] => 2019-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16548
[patent_no_of_claims] => 2
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16269744
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/269744 | Purinone derivative | Feb 6, 2019 | Issued |
Array
(
[id] => 18412142
[patent_doc_number] => 11666669
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-06-06
[patent_title] => Cromolyn derivatives and related methods of imaging and treatment
[patent_app_type] => utility
[patent_app_number] => 16/259542
[patent_app_country] => US
[patent_app_date] => 2019-01-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 18035
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16259542
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/259542 | Cromolyn derivatives and related methods of imaging and treatment | Jan 27, 2019 | Issued |
Array
(
[id] => 17466682
[patent_doc_number] => 11273139
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-03-15
[patent_title] => Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases
[patent_app_type] => utility
[patent_app_number] => 16/257988
[patent_app_country] => US
[patent_app_date] => 2019-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 8452
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 37
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16257988
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/257988 | Halogenated esters of cyclopropanated unsaturated fatty acids for use in the treatment of neurodegenerative diseases | Jan 24, 2019 | Issued |